Taurolidine

Generic Name: Taurolidine

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₆N_₄O_₄S_₂

CAS Number: 19388-87-5

Unique Ingredient Identifier: 8OBZ1M4V3V

Overview

Taurolidine has been investigated for the prevention of Central Venous Catheter, Home Parenteral Nutrition, and Catheter-Related Infections.

Indication

Not Available

Associated Conditions

Infection
Soft Tissues Infections
Tissue Adhesions
Perioperative infection

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials	2024/11/27	NCT06707480	N/A	AVAILABLE	CorMedix
Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection	2022/10/12	NCT05576194	N/A	Completed	Prof. Dr. Hendrik Bonnemeier
Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.	2018/05/29	NCT03539718	Phase 4	UNKNOWN	Ain Shams University
Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children	2015/08/04	NCT02515201	Phase 4	UNKNOWN	Hospital de Clinicas de Porto Alegre
Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase	2014/01/14	NCT02036255	Phase 3	Completed	Universitair Ziekenhuis Brussel
Taurolidine Lock in Long Term Parenteral Nutrition	2013/12/11	NCT02009189	Phase 4	Completed	Stanley Dudrick's Memorial Hospital
The AOT (Acridine Orange and Taurolidine) Trial	2006/05/03	NCT00321165	Phase 3	Completed	Radboud University Medical Center
Taurolidine in Treating Patients With Recurrent or Progressive Glioma	2004/03/19	NCT00022360	Phase 1	Completed	Memorial Sloan Kettering Cancer Center
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	2004/02/16	NCT00021034	Phase 1	Completed	Memorial Sloan Kettering Cancer Center

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
DEFENCATH	CorMedix Inc.	72990-103	INTRALUMINAL	40.5 mg in 3 mL	12/21/2023
DEFENCATH	CorMedix Inc.	72990-105	INTRALUMINAL	67.5 mg in 5 mL	12/21/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.